Document is current

Any future updates will be listed below

Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

Crossref DOI link: https://doi.org/10.1186/s13075-022-02940-5

Published Online: 2022-11-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark